Drugs / Shigella4V2
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06523231 | Apr → Aug 2025 | shigellosis | LimmaTech Biologics AG | Completed | No outcome recorded |
| Phase 2 | NCT06615375 | Nov 2024 → Apr 2026 overdue | shigellosis | LimmaTech Biologics AG | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shigella4V2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06523231 ↗ |
| Modality | Vaccine | “Shigella4V2 is the second generation of a tetravalent bioconjugate vaccine including O-antigen-polysaccharides of the most predominant Shigella serotypes.” NCT06523231 ↗ |
| Route | Intramuscular | “injected intramuscularly in the deltoid muscle” NCT06615375 ↗ |